Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects
Maria Mironova(National Institutes of Health), Yaron Rotman(National Institute of Diabetes and Digestive and Kidney Diseases), Maren C. Podszun(University of Hohenheim), Rebecca J. Brown(National Institutes of Health), Allison Wing(Yale University), Brent S. Abel(National Institutes of Health)
Cited by 3
Related Papers
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519
Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa–Dependent Manner
|Gastroenterology|2009|271
The liver diseases of lipodystrophy: The long-term effect of leptin treatment
|Journal of Hepatology|2013|165
Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes.
|Diabetes|2000|97
Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity
|Journal of Lipid Research|2020|27